KEITH L. BROWNLIE, C.P.A.

Corporate Board Profile

Tech Score: 0/100

SOLIGENIX, INC.

Filing Date	Source Excerpt
2012-05-11	Keith L. Brownlie, C.P.A. has been a director since June 2011. Mr. Brownlie currently serves as a member of the Board of Directors of Epicept Corporation, a publicly traded, specialty pharmaceutical company focused on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain, a position he has held since April 2011. The Audit Committee is comprised of Keith L. Brownlie (Chair), Robert J. Rubin and Virgil D. Thompson. The following table contains information concerning the compensation of the non-employee directors during the fiscal year ended December 31, 2011. Keith Brownlie Fees Earned Paid in Cash $9,245, Option Awards $46,944, Total $56,189.

Filing Date

Source Excerpt

2012-05-11

Keith L. Brownlie, C.P.A. has been a director since June 2011. Mr. Brownlie currently serves as a member of the Board of Directors of Epicept Corporation, a publicly traded, specialty pharmaceutical company focused on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain, a position he has held since April 2011. The Audit Committee is comprised of Keith L. Brownlie (Chair), Robert J. Rubin and Virgil D. Thompson. The following table contains information concerning the compensation of the non-employee directors during the fiscal year ended December 31, 2011. Keith Brownlie Fees Earned Paid in Cash $9,245, Option Awards $46,944, Total $56,189.

Data sourced from SEC filings. Last updated: 2025-12-07